There are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of the drug effect of antimicrobial therapy for mild community-acquired pneumonia (CAP). However, there is evidence that ineffective therapies, selected on the basis of the ratio of 24-h area under the concentration curve to minimum inhibitory concentration, associated with a discordant (nonsusceptible in vitro) specific agent (or no therapy) for mild CAP due to Streptococcus pneumoniae are associated with increased risk of progression to serious CAP. The relatively high rate of clinical success associated with appropriate antimicrobial treatment of mild CAP renders a standard outcome measure of clinical success an unlikely way to differentiate new agents. However, there may be an advantage in composite outcome assessments for mild CAP. Compositeoutcomes end points that include time to resolution of morbidity, the use of patient reported-outcomes instruments, and biomarkers are recommended for future studies. Because the composite rate of success in recent randomized clinical trials exceeds 90%, it would seem that a noninferiority margin of 10% is reasonable for trials for mild CAP.
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eases Society of America (IDSA) and the American Thoracic Society (ATS) [3] .
This review will present a clinician's perspective on the role of antibiotics in randomized, controlled trials involving patients with mild pneumonia. We focus on controversial issues that make interpretation of the results of these trials difficult, suggest potential designs for a superiority trial, and offer reasonable data on progression of untreated cases, to define an evidencebased margin for a noninferiority trial.
GENERAL CONSIDERATIONS OF MILD PNEUMONIA
As in the case of the patient presented in scenario I in this workshop (a patient with CAP of Fine class I), ∼75%-80% of patients with CAP are given antibiotic treatment as outpatients. Here, we define mild pneumonia as cases of Fine class I or II [4] . The most-common pathogens associated with mild pneumonia in Fine classes I, II, and III are shown in table 1 [3, 5] .
There are vivid observational descriptions of the benefit of antibiotic therapy for treatment of serious pneumococcal CAP after the introduction of penicillin in the 1940s. Similar descriptions for "mild" pneumonia are difficult to find. Therefore, the antibiotic treatment effect in mild infections is not as well appreciated. Because the mortality rate of mild pneumonia in modern studies is !1%, other outcome measures are necessary to assess the benefit of antimicrobial therapy for mild CAP.
RELATIVE BENEFIT OF ANTIMICROBIAL THERAPY FOR MILD PNEUMONIA
The patient in scenario I has a low risk of death. Nevertheless, the patient has significant morbidity, which, if Streptococcus pneumoniae is present as the pathogen, puts him at risk for progressive disease if he is not given an active antibiotic. Studies of CAP treated in the outpatient setting suggest that 2%-8% of patients develop progressive illness and subsequently require hospitalization because of failure of outpatient antibiotic therapy [6] [7] [8] . Because there are no well-controlled randomized trials comparing placebo with active therapy for mild CAP, it is difficult to assess the absolute value of antimicrobial agents in such cases. Nevertheless, BMJ Clinical Evidence Handbook, an assessment of evidence-based medicine, concludes that use of antibiotic is beneficial in the outpatient setting (compared with no use of antibiotics). The statement acknowledges that this conclusion is based on "consensus" but further adds that randomized, controlled trials are "likely to be considered unethical" [9, p. 448 ].
An alternative method of assessing the importance of antibiotic effect is to analyze discordant antimicrobial therapy. What happens to a patient with S. pneumoniae infection when the patient is given treatment with an antimicrobial that is not active in vitro against S. pneumoniae? Few treatment failures are observed when appropriate b-lactam agents are used [10, 11] . On the other hand, the prevalence of macrolide resistance among S. pneumoniae isolates is reported to be 20%-40%, and reports of associated clinical failures are increasing [12] .
There are no prospective, population-based studies that provide an actual incidence of treatment failures associated with macrolide-resistant S. pneumoniae when a macrolide is used as first-line therapy for mild CAP. There are retrospective case series involving outpatients that assess the consequence of macrolide failures. Iannini et al. [13] identified 122 patients with CAP caused by S. pneumoniae admitted to the hospital after failure of outpatient macrolide therapy. There was a notable increase in macrolide resistance (160%) and mortality (5.7%) after oral macrolide treatment failure. Of clinical significance, the rate of presentation with S. pneumoniae bacteremia was 52% among those with outpatient treatment failures. The mean pneumonia severity index (PSI) score at first presentation of symptoms was 2.0 in this population, and, by the time they were hospitalized (mean, 4.7 days after onset of illness), their mean PSI score was 2.9 [13] . Clearly, macrolide treatment for macrolide-resistant S. pneumoniae did little to interrupt the progressive course of initially mild CAP, leading to hospital admission.
Daneman et al. [14] developed a theoretical model linking prevalence of macrolide-resistant S. pneumoniae to outcomes among patients with CAP, on the basis of an epidemiological concept of risk difference if patients with CAP due to macrolide-resistant S. pneumoniae were given treatment with a macrolide. Under a proposed threshold of 25% resistance (which is presently the case in North America), the risk difference for macrolide empirical therapy would be 1.2% for excess death and 3.3% for prolonged clinical course.
File et al. [15] evaluated the effects of underlying lung disease, pathogen characteristics, and the ratio of area under the concentration curve to minimum inhibitory concentration (AUIC) on the transition state-from chronic obstructive pulmonary disease to CAP requiring hospitalization-among 343 patients given treatment as outpatients. There was particular interest in determining the impact of S. pneumoniae on the progression of acute exacerbation of chronic bronchitis to CAP, in relation to both underlying lung disease and the AUIC of initial antimicrobial therapy. The observations suggest that patients with underlying chronic obstructive pulmonary disease who developed infection due to S. pneumoniae had inferior clinical outcomes if they were given treatment with suboptimal antimicrobial therapy. This subset of patients with chronic obstructive pulmonary disease may readily transition to having CAP unless they receive treatment with sufficient antipneumococcal activity, defined here as AUIC 1100. Thus, ineffective antimicrobial therapy for S. pneumoniae infection led to progressive CAP requiring hospitalization. Collectively, these studies are consistent with the hypothesis that mild respiratory infections caused by S. pneumoniae can progress rapidly to severe CAP if not treated appropriately.
Even though S. pneumoniae is the etiological pathogen in a small proportion of outpatients in PSI risk class I or II, most of the mortality among patients in these low-risk categories occurs among those with pneumococcal disease. We examined 3 groups of patients with mild initial respiratory infection that progressed to S. pneumoniae bacteremia: (1) patients admitted to the hospital with no previous outpatient therapy, (2) patients admitted after previous antibiotic therapy, and (3) patients given successful treatment in the community who did not require hospitalization.
The first cohort consisted of 609 patients who were not given treatment with antibiotics ( ) before hospitalization AUIC p 0 with S. pneumoniae bacteremia. The second consisted of 83 patients who received antibiotic treatment, but the antibiotics had discordant activity (i.e., the isolate was not susceptible in vitro) against S. pneumoniae in blood cultures (AUIC !100), and they subsequently presented with bacteremia. The third cohort consisted of 37 patients with a PSI score of 1 or 2 who were bacteremic but were given antibiotic treatment with AUIC 1100 at the time the bacteremia was defined. Most of the patients in the third cohort were cured by oral antibiotic therapy in the community, but some were hospitalized, and several of those hospitalized died. The survival data from all 3 cohorts of patients with S. pneumoniae bacteremia are presented in figure 1 . It should be noted that all hospitalized patients met criteria for moderate-to-severe CAP and immediately received multiple antibiotics, and essentially all received hospital treatment regimens that achieved AUIC 1100. Some patients may have recovered because of the antibiotic therapy, and others might have died regardless (early deaths were considered a consequence of inadequate outpatient treatment).
Time to mortality is the recorded end point for all 3 cohorts, and, in figure 1, mortality is recorded in relation to the day of first respiratory illness in the community. Patients begin to die by day 4 after onset of respiratory symptoms; at day 4, mortality among untreated patients ( ) was 2%-3%. By con-AUIC p 0 trast, Austrian and Gold [16] noted a 9% mortality rate at day 4 in the preantibiotic era and in the early days of low-dose penicillin. At the time of this cohort analysis, there was no accepted measure of underlying illness, such as PSI score, and there were no accepted means of quantifying the interaction between MIC and antibiotic exposure, such as AUIC. Thus, it is difficult to determine whether S. pneumoniae has become a less lethal pathogen or whether nonantibiotic medical care has improved for these patients. Most likely, the patients of Austrian and Gold were further along the progression curve when they presented with illness, because, at the time, there was no readily available treatment for CAP. In figure 2 , we considered all patients with S. pneumoniae infection, regardless of whether their infection was defined by respiratory tract cultures, bacteremia, or both. All 3 groups are larger than the respective groups who presented with bacteremia, because there were 660 patients in the untreated group with , 179 patients in the discordant-treatment group AUIC p 0 with AUIC !100, and 200 patients in the group with AUIC у100. Figure 2 may be more relevant than is figure 1 to the question of S. pneumoniae in the community, because there are 1100 patients with AUIC у100 in the community and thus there is a more representative sample of patients with lower PSI scores and younger ages. The lowest mortality rate would be expected among the group with AUIC у100 in the community, and that is what was found. The highest overall mortality rate was among the group with , and those AUIC p 0 with AUIC !100 were more similar to those with . Other than a slightly lower overall mortality, these AUIC p 0 data show behavior patterns similar to those of S. pneumoniae infections in patients with and patients without bacteremia, which should allow a modern perspective on the mortality associated with untreated and partially treated S. pneumoniae infection in the community. These observations provide further evidence that less-effective antimicrobial therapy (or no treatment) for mild CAP is associated with an increased risk of transition to serious CAP.
Patients in the cohorts with and AUIC у100 were AUIC p 0 similar in their underlying diseases and overall demographic characteristics, as shown in table 2. However, it was also clear that patients with AUIC !100 were generally older and more chronically ill before the onset of S. pneumoniae infection. Furthermore, the subset of these patients who developed bacteremia were overall more ill than were those who presented with CAP, diagnosed on the basis of respiratory culture isolates alone ( ). Clearly, underlying disease states have an impact on P ! .001 early mortality, but it is less important overall than is the match between early antibiotic activity and organism MIC.
We also examined the impact of underlying PSI score on mortality among patients with S. pneumoniae infection, after correcting for differences in AUIC. These data are shown in table 3. As can be appreciated from this table, the AUIC groups were balanced, in that !15% of any group was in PSI class IV or V. More than 60% of all patients with S. pneumoniae infection, regardless of AUIC, were in PSI class I or II; thus, by all criteria, this population can be categorized as having mild pneumonia at the time the illness began. The mean PSI score of each AUIC group was ∼2.1; thus, AUIC was very important in determining whether the treatment failed and the patient was hospitalized or the patient was not hospitalized at all. These relationships were not accounted for by PSI, and, in fact, S. pneumoniae bacteremia was approximately evenly distributed among the groups based on PSI. Thus, our data further establish that underlying severity of disease does not predict the presence of S. pneumoniae, and it does not predict mortality due to S. pneumoniae infection, when AUIC is considered. Antibiotic action (or lack thereof) is the primary determinant in progression from mild to severe CAP when the pathogen is S. pneumoniae.
POTENTIAL DESIGNS FOR A SUPERIORITY TRIAL FOR MILD CAP
These cases illustrate the dilemma of clinical trial design with a noninferiority model. At the time of enrollment, it is not possible to determine which of the patients with mild respiratory infection and low PSI scores have S. pneumoniae infection. The patients with mild initial disease due to S. pneumoniae and mild initial disease associated with other organisms (or patients who have negative results of culture) appear similar on the basis of their presenting clinical symptoms and PSI scores. Thus, any putative placebo-controlled trial becomes a superiority trial involving the subset of patients whose respi- Neoplastic disease 81 (12) 19 (11) 11 (6) .025
Liver disease 60 (9) 2 (1) 10 (5) !.001
Heart failure 50 (8) 16 (9) 15 (8 After the time course of untreated CAP is established, as in figures 1 and 2, it is difficult for us to conceive of a rate of spontaneous resolution whenever a placebo is given to a patient with true S. pneumoniae respiratory tract infection. In contrast, the data of Austrian and Gold [16] for preantibiotic era cohorts show a survival rate of 57%-83% for patients given placebo as outpatients, followed by penicillin given at hospital admission, primarily depending on patient age being 40-70 years. Our data on discordant therapy with macrolides argue that the survival rate is not dramatically better than this for patients given antibiotic treatment with AUIC !100, although the incidence of death from pneumococcal disease in a clinical population depends more on how many patients are infected with an S. pneumoniae strain resistant to the antibiotic chosen. In fact, when enrolled in CAP trials, as few as 10% of patients with mild cases and PSI scores of 1-2 have S. pneumoniae isolated in baseline cultures, even when radiographic findings indicate the presence of pneumonia. However, these patients probably account for most of the mortality and much of the morbidity (i.e., delayed resolution of illness and possible progression to serious disease). Thus, even with the subset of patients with mild CAP, if any of the study cases are caused by S. pneumoniae, our data argue against conducting a placebo-controlled trial. Failures will occur and have clear links to the AUIC values, although most patients experiencing treatment failure probably will not die if they are promptly hospitalized and given ag- gressive intravenous antimicrobial therapy. Noninferiority margins can be set for trials comparing antibiotics, but the true incidence of S. pneumoniae must be considered at the stage of trial design, because the small subset of patients infected with this pathogen drives the outcomes of interest in the population and should be studied separately. In addition to S. pneumoniae, another common cause of mild CAP is the group of "atypical" pathogens, especially Mycoplasma pneumoniae. Indeed, in part because of the intrafamilial epidemiology and the age of the patient in scenario I, M. pneumoniae is a distinctly possible etiology. However, there is considerable debate about the need to treat infection with this organism in mild cases of CAP.
PREVIOUS PLACEBO-CONTROLLED TRIALS FOR MILD CAP DUE TO M. PNEUMONIAE
There are several historical studies that showed that active therapy was superior to placebo or "inactive" therapy for CAP caused by M. pneumoniae [17] [18] [19] [20] . In 1961, Kingston et al. [17] published a double-blind study of demethylchortetracycline versus placebo (capsules "of like appearance") in a study of 109 military recruits with atypical pneumonia due to M. pneumoniae. Patients given treatment with the antimicrobial had significant reduction in the duration of fever (2.1 vs. 8.1 days) and cough (9.7 vs. 21.9 days) (table 4) . Three other studies demonstrate more-rapid resolution of CAP due to M. pneumoniae when it is treated with tetracycline or erythromycin, compared with no antimicrobial therapy or penicillin [18] [19] [20] .
POTENTIAL SUPERIORITY TRIAL TO ASSESS THE IMPACT OF TREATING "ATYPICAL" PNEUMONIA
The fact that appropriate therapy can shorten the clinical course for patients with CAP due to M. pneumoniae is one reason that the recommendations for empirical therapy for mild CAP in the recent IDSA/ATS guidelines include "atypical" coverage. This is a key difference between the IDSA/ATS and European guidelines [21] . For mild CAP, the IDSA/ATS approach is to empirically treat both S. pneumoniae and the atypical pathogens commonly associated with outpatient CAP: M. pneumoniae and Chlamydia pneumoniae. By contrast, the European guidelines primarily focus on empirical therapy for S. pneumoniae and place less emphasis on the empirical treatment of atypical organisms. Two recent meta-analyses support the European approach [22, 23] . These analyses have limitations; the studies used clinical end points that were several weeks after initiation of the study agents and end points that were not designed to compare the time to response. Mortality is not a sensitive end point for randomized trials for mild CAP, especially when many patients are not infected with S. pneumoniae. More recently, a large, international observational study of mostly hospitalized patients with CAP found better clinical outcomes (including decreases in time to clinical stability, length of hospital stay, and mortality) associated with antimicrobial regimens with atypical coverage, compared with therapy that did not have atypical coverage [24] .
A well-designed prospective study is required to definitively determine the need to empirically treat the atypical pathogens [22] . A potential study to assess superiority in this regard might be a double-blind, randomized, controlled trial that compares amoxicillin plus a macrolide versus amoxicillin plus placebo and measures the time to resolution of morbidity (and other possible measures listed below), rather than success at a later time period.
POTENTIAL DESIGN TO EVALUATE NEW ANTIMICROBIALS
In situations in which there is mild CAP and ∼10% of cases have confirmed S. pneumoniae, the use of appropriate active control drugs makes "superior" results highly unlikely, because the clinical success rates of the presently recommended antimicrobials is high (190%) [25] [26] [27] . This relatively high rate of clinical success, as well as the low mortality rate associated with mild CAP, render a standard outcome measure of clinical success (usually at 7-14 days after cessation of study drug) an unlikely way to differentiate new agents, which actually may have some advantage. It then becomes necessary to consider other outcome measures to assess the possible superiority of a new agent. It seems reasonable to construct composite-outcome end points that include time to resolution of morbidity, the use of patient reported-outcomes instruments, and the possible serial measurement of worsening in the time course of biomarkers, such as procalcitonin [28] [29] [30] [31] [32] [33] . A composite end point that uses objective measures or scoring systems will also reduce bias of subjective assessment of "clinical improvement." Several studies have previously used patient-reported outcomes or symptom-scoring-systems outcomes as primary end points [28] [29] [30] [31] . A composite end point that includes some or all of these measures may allow for differentiation of new agents, but probably only in the case where one of the agents is clearly more active against S. pneumoniae or other pathogens driving the progression and/or resolution of disease.
Whether new studies are designed as superiority or noninferiority trials, optimal trial design requires double-blind assessment and measures to ensure that enrolled patients have CAP and not acute bronchitis. The use of a biomarker such as procalcitonin may help to ensure that enrolled patients are (1) more likely to have bacterial infection and (2) more likely to benefit from antimicrobial treatment.
Superior results may occur even if a study is designed as a noninferiority study. Several randomized, controlled trials of a respiratory fluoroquinolone have shown superior outcomes, depending on the end point measured. In an open-label, randomized trial of a respiratory fluoroquinolone versus a cephalosporin with or without a macrolide, File et al. [34] found that levofloxacin was superior with regard to the primary end point-clinical success at 5-7 days after the end of therapy with the study drug-as well as microbiological success in the perprotocol population. Of interest, slightly 150% of these patients received only oral therapy, suggesting that they had mild CAP (this study was performed before publication of the Fine classification system). When only patients given oral therapy were evaluated, clinical success was achieved in 133 (96.4%) of 138 patients given levofloxacin treatment and in 104 (89.7%) of 116 patients given the comparator treatment ( ) (S. Thus, there was a "superior" result even for the nonhospitalized population with less-serious CAP. In this study, the comparator for patients given only oral therapy was cefuroxime with or without erythromycin. Subsequent to this study, Yu et al. [31] demonstrated that cefuroxime is inferior to third-generation cephalosporins for the treatment of pneumococcal bacteremia. Other double-blind, randomized, controlled trials, mostly involving patients given treatment within the hospital, have shown superior results for one treatment arm by measuring time to resolution of fever and composite clinical scores [35, 36] .
ARE THERE ADEQUATE DATA TO DEFINE AN EVIDENCED-BASED MARGIN FOR A NONINFERIORITY TRIAL?
In noninferiority clinical trials, the margin of noninferiority is based on the activity of the comparator in placebo-controlled trials. In the case of CAP, this activity is not available, because there are no placebo-controlled trials using standard outcome measures at a predetermined time point that precisely establish the treatment benefit of the active agents. However, there are multiple randomized, controlled trials indicating that the use of presently recommended drugs for treatment of mild CAP is associated with high rates of success. Because the composite rate of success in these recent trials is 190%, it would seem that a noninferiority margin of 10% is reasonable.
CONCLUSION
Although there are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of drug effect of antimicrobial therapy for mild CAP, there is general agreement among clinicians that the presently recommended antimicrobial agents provide a treatment benefit to our patients. This view is reinforced by examination of the time course of untreated community-onset S. pneumoniae infections among patients who are eventually hospitalized. Because of the low mortality rate among patients with CAP of Fine classes I and II, treatment outcomes can be measured by speed of resolution of morbidity, patient-reported outcomes, or symptom scoring systems. Among patients who have bacterial pneumonia caused by S. pneumoniae, the risk of progression to serious disease precludes the use of placebo-controlled trials. The consideration of biomarkers, such as procalcitonin, should be explored as an objective measurement of response in subsequent clinical trials.
